Macroscopic type is implicated in the prognostic impact of initial chemotherapy on peritoneal lavage cytology-positive gastric cancer with no other noncurative factors.

Autor: Kano, Yosuke, Ichikawa, Hiroshi, Aizawa, Masaki, Muneoka, Yusuke, Usui, Kenji, Hanyu, Takaaki, Ishikawa, Takashi, Yabusaki, Hiroshi, Kobayashi, Kazuaki, Kuwabara, Shirou, Makino, Shigeto, Kawachi, Yasuyuki, Miura, Kohei, Tajima, Yosuke, Shimada, Yoshifumi, Sakata, Jun, Wakai, Toshifumi
Předmět:
Zdroj: International Journal of Clinical Oncology; Jun2024, Vol. 29 Issue 6, p790-800, 11p
Abstrakt: Background: Initial chemotherapy (Initial-C) followed by surgery is a promising treatment strategy for peritoneal lavage cytology-positive gastric cancer (CY1 GC) with no other noncurative factors. The aim of this study was to investigate the survival advantage of Initial-C compared to initial surgery (Initial-S) for this disease according to the macroscopic type, which was associated with prognosis and the efficacy of chemotherapy in GC. Methods: One hundred eighty-nine patients who were diagnosed with CY1 GC with no other noncurative factors at four institutions from January 2007 to December 2018 were enrolled. The patients were divided into a macroscopic type 4 group (N = 48) and a non-type 4 group (N = 141). The influence of initial treatment on overall survival (OS) in each group was evaluated. Results: In the type 4 group, the 5-year OS rates of Initial-C (N = 35) and Initial-S (N = 13) were 11.6% and 0%, respectively (P = 0.801). The multivariate analysis could not show the survival advantage of Initial-C. In the non-type 4 group, the 5-year OS rates of Initial-C (N = 41) and Initial-S (N = 100) were 48.4% and 29.0%, respectively (P = 0.020). The multivariate analysis revealed that Initial-C was independently associated with prolonged OS (hazard ratio, 0.591; 95% confidence interval, 0.375–0.933: P = 0.023). Conclusions: Initial-C improves the prognosis of non-type 4 CY1 GC with no other noncurative factors. On the other hand, further development of effective chemotherapeutic regimens and innovative treatment strategies are required for type 4 CY1 GC. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index